vs
Side-by-side financial comparison of SPRUCE POWER HOLDING CORP (SPRU) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
SPRUCE POWER HOLDING CORP is the larger business by last-quarter revenue ($24.0M vs $13.7M, roughly 1.8× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -28.6%, a 104.3% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-3.3M).
Spruce Finance is an American consumer finance company specializing in the residential solar finance and efficiency home improvement sectors in the U.S.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SPRU vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.0M | $13.7M |
| Net Profit | $-6.9M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 9.4% | -86.5% |
| Net Margin | -28.6% | 75.7% |
| Revenue YoY | 20.4% | — |
| Net Profit YoY | -15.8% | 179.1% |
| EPS (diluted) | $-0.38 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.0M | $13.7M | ||
| Q3 25 | $30.7M | $19.1M | ||
| Q2 25 | $33.2M | $8.1M | ||
| Q1 25 | $23.8M | $2.9M | ||
| Q4 24 | $20.0M | — | ||
| Q3 24 | $21.4M | — | ||
| Q2 24 | $22.5M | — | ||
| Q1 24 | $18.3M | — |
| Q4 25 | $-6.9M | $10.4M | ||
| Q3 25 | $-860.0K | $-16.3M | ||
| Q2 25 | $-3.0M | $-15.8M | ||
| Q1 25 | $-15.3M | $-13.3M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-53.5M | — | ||
| Q2 24 | $-8.6M | — | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 54.9% | — | ||
| Q1 24 | 51.5% | — |
| Q4 25 | 9.4% | -86.5% | ||
| Q3 25 | 27.6% | -10.1% | ||
| Q2 25 | 26.8% | -177.7% | ||
| Q1 25 | -7.1% | -472.7% | ||
| Q4 24 | -31.4% | — | ||
| Q3 24 | -173.8% | — | ||
| Q2 24 | -14.9% | — | ||
| Q1 24 | -19.7% | — |
| Q4 25 | -28.6% | 75.7% | ||
| Q3 25 | -2.8% | -85.4% | ||
| Q2 25 | -8.9% | -196.0% | ||
| Q1 25 | -64.4% | -452.7% | ||
| Q4 24 | -29.7% | — | ||
| Q3 24 | -250.4% | — | ||
| Q2 24 | -38.2% | — | ||
| Q1 24 | -13.4% | — |
| Q4 25 | $-0.38 | $-3.74 | ||
| Q3 25 | $-0.05 | $-0.11 | ||
| Q2 25 | $-0.17 | $-0.16 | ||
| Q1 25 | $-0.84 | $-0.18 | ||
| Q4 24 | $-0.36 | — | ||
| Q3 24 | $-2.88 | — | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.8M | $137.5M |
| Total DebtLower is stronger | $695.5M | — |
| Stockholders' EquityBook value | $121.3M | $35.3M |
| Total Assets | $837.3M | $154.7M |
| Debt / EquityLower = less leverage | 5.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.8M | $137.5M | ||
| Q3 25 | $53.6M | $103.8M | ||
| Q2 25 | $53.5M | $121.6M | ||
| Q1 25 | $61.9M | $89.1M | ||
| Q4 24 | $72.8M | — | ||
| Q3 24 | $113.7M | — | ||
| Q2 24 | $116.6M | — | ||
| Q1 24 | $120.6M | — |
| Q4 25 | $695.5M | — | ||
| Q3 25 | $705.6M | — | ||
| Q2 25 | $717.1M | — | ||
| Q1 25 | $723.8M | — | ||
| Q4 24 | $730.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $121.3M | $35.3M | ||
| Q3 25 | $124.9M | $-8.1M | ||
| Q2 25 | $125.0M | $7.1M | ||
| Q1 25 | $130.8M | $10.7M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $151.6M | — | ||
| Q2 24 | $204.6M | — | ||
| Q1 24 | $213.0M | — |
| Q4 25 | $837.3M | $154.7M | ||
| Q3 25 | $857.1M | $133.7M | ||
| Q2 25 | $862.6M | $133.8M | ||
| Q1 25 | $878.0M | $103.7M | ||
| Q4 24 | $898.5M | — | ||
| Q3 24 | $806.8M | — | ||
| Q2 24 | $858.4M | — | ||
| Q1 24 | $867.9M | — |
| Q4 25 | 5.74× | — | ||
| Q3 25 | 5.65× | — | ||
| Q2 25 | 5.74× | — | ||
| Q1 25 | 5.53× | — | ||
| Q4 24 | 5.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-2.0M |
| Free Cash FlowOCF − Capex | $-3.3M | $-2.1M |
| FCF MarginFCF / Revenue | -13.7% | -15.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-3.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.3M | $-2.0M | ||
| Q3 25 | $11.2M | $-17.5M | ||
| Q2 25 | $-2.3M | $-14.5M | ||
| Q1 25 | $-9.1M | $29.0M | ||
| Q4 24 | $-13.5M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-22.2M | — |
| Q4 25 | $-3.3M | $-2.1M | ||
| Q3 25 | $11.2M | — | ||
| Q2 25 | $-2.4M | $-14.9M | ||
| Q1 25 | $-9.2M | $29.0M | ||
| Q4 24 | $-13.6M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | $-22.3M | — |
| Q4 25 | -13.7% | -15.3% | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | -7.3% | -184.0% | ||
| Q1 25 | -38.7% | 988.3% | ||
| Q4 24 | -68.3% | — | ||
| Q3 24 | -5.1% | — | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | -121.7% | — |
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.3% | 5.0% | ||
| Q1 25 | 0.4% | 0.8% | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
